ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Treatment decision-making in advanced thyroid cancer with oncogenic alterations "
Episode Synopsis
In today’s episode, we welcome Dr. Antonio Matrone, an endocrinologist at the University of Pisa, to discuss the many factors involved in treatment decision-making and strategies for the management of patients with advanced thyroid cancer where an oncogenic driver has been identified.
References
Matrone A et al. Differentiated thyroid cancer, from active surveillance to advanced therapy: Toward a personalized medicine. Front Endocrinol (Lausanne) 2019;10:884
Sherman SI. Evolution of targeted therapies for thyroid carcinoma. Trans Am Clin Climatol Assoc 2019;130:255–265
Filetti S et al. ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. Ann Oncol 2022;33(7):P674–P684
Capdevila J et al. Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era. Cancer Treat Rev 2022;106:102380
Dabrafenib highlights of prescribing information. 2022
Wirth LJ et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med 2020;383:825–835
Josfeld L et al. Cancer patient’s perspective on shared decision-making and decision aids in oncology. J Cancer Res Clin Oncol 2021;147:1725–1732
Target Audience:
Oncologists, pathologists and other HCPs involved in the diagnosis of RET and TRK cancers, with a focus on community practitioners.
Learning Objective:
Recall thyroid RET and TRK fusion-positive cancer diagnosis and relevant genomic testing guidelines and identify ways to adapt the guidelines to local settings
Discuss “precision medicine” and new technologies, including “liquid biopsy”
Review the organisation of care and strategies for more efficient care delivery
These learning objectives are for the podcast series. This episode focuses on the first and third objective.
Funding Information:
This episode is supported by an educational grant from Eli Lilly, who have had no influence on the content or choice of faculty.
Staff Disclosure:
Dr. Matrone declares the following:
Consultant - Eli Lilly
References
Matrone A et al. Differentiated thyroid cancer, from active surveillance to advanced therapy: Toward a personalized medicine. Front Endocrinol (Lausanne) 2019;10:884
Sherman SI. Evolution of targeted therapies for thyroid carcinoma. Trans Am Clin Climatol Assoc 2019;130:255–265
Filetti S et al. ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. Ann Oncol 2022;33(7):P674–P684
Capdevila J et al. Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era. Cancer Treat Rev 2022;106:102380
Dabrafenib highlights of prescribing information. 2022
Wirth LJ et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med 2020;383:825–835
Josfeld L et al. Cancer patient’s perspective on shared decision-making and decision aids in oncology. J Cancer Res Clin Oncol 2021;147:1725–1732
Target Audience:
Oncologists, pathologists and other HCPs involved in the diagnosis of RET and TRK cancers, with a focus on community practitioners.
Learning Objective:
Recall thyroid RET and TRK fusion-positive cancer diagnosis and relevant genomic testing guidelines and identify ways to adapt the guidelines to local settings
Discuss “precision medicine” and new technologies, including “liquid biopsy”
Review the organisation of care and strategies for more efficient care delivery
These learning objectives are for the podcast series. This episode focuses on the first and third objective.
Funding Information:
This episode is supported by an educational grant from Eli Lilly, who have had no influence on the content or choice of faculty.
Staff Disclosure:
Dr. Matrone declares the following:
Consultant - Eli Lilly
More episodes of the podcast Oncology Knowledge into Practice Podcast
The ESMO 2022 Clinical Practice Guidelines for use of systemic therapy in advanced thyroid care
21/03/2023
Working together in the management of thyroid cancer: An oncologist and pathologist in conversation
23/09/2022
Tissue is Never the Issue
27/06/2022
Thyroid cancer: testing for biomarkers
01/04/2022
In God we trust